Clinical Trial Update: S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium [Phase 2]

View source ↗

Summary

Phase 2 trial of Romidepsin (FR901228) in advanced urothelial cancers was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Transitional Cell Carcinoma of the Renal Pelvis and Ureter
• Urethral Cancer

Drugs mentioned

• Romidepsin (Istodax) (romidepsin)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter | Phase 2 | Status: TERMINATED